These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27342034)

  • 1. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
    Chevret E; Merlio JP
    J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.
    Prasad A; Rabionet R; Espinet B; Zapata L; Puiggros A; Melero C; Puig A; Sarria-Trujillo Y; Ossowski S; Garcia-Muret MP; Estrach T; Servitje O; Lopez-Lerma I; Gallardo F; Pujol RM; Estivill X
    J Invest Dermatol; 2016 Jul; 136(7):1490-1499. PubMed ID: 27039262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.
    Gros A; Laharanne E; Vergier M; Prochazkova-Carlotti M; Pham-Ledard A; Bandres T; Poglio S; Berhouet S; Vergier B; Vial JP; Chevret E; Beylot-Barry M; Merlio JP
    PLoS One; 2017; 12(3):e0173171. PubMed ID: 28301507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.
    Kiel MJ; Sahasrabuddhe AA; Rolland DCM; Velusamy T; Chung F; Schaller M; Bailey NG; Betz BL; Miranda RN; Porcu P; Byrd JC; Medeiros LJ; Kunkel SL; Bahler DW; Lim MS; Elenitoba-Johnson KSJ
    Nat Commun; 2015 Sep; 6():8470. PubMed ID: 26415585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sézary syndrome: old enigmas, new targets.
    Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sézary Syndrome: Clinical and Biological Aspects.
    Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
    Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in Sezary syndrome.
    Iżykowska K; Przybylski GK
    Leuk Lymphoma; 2011 May; 52(5):745-53. PubMed ID: 21323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
    Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
    Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLCG1 Gene Mutations in Cutaneous T-Cell Lymphomas Revisited.
    Tensen CP
    J Invest Dermatol; 2015 Sep; 135(9):2153-2154. PubMed ID: 26269406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
    Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
    Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.